Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NUVL NASDAQ:PRAX NASDAQ:TGTX NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNUVLNuvalent$123.500.0%$108.76$71.13▼$123.69$9.76B1.155.19 million shs1.65 million shsPRAXPraxis Precision Medicines$334.79-4.5%$314.47$37.19▼$366.52$9.77B2.71701,758 shs740,097 shsTGTXTG Therapeutics$54.94-1.4%$43.01$25.28▼$57.38$8.53B1.683.02 million shs2.57 million shsTRVITrevi Therapeutics$18.65+0.1%$14.88$5.47▼$19.26$2.65B1.042.09 million shs3.10 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNUVLNuvalent-0.01%+0.05%+11.88%+16.91%+61.86%PRAXPraxis Precision Medicines-4.50%+9.63%-4.34%+4.86%+696.17%TGTXTG Therapeutics-1.40%+1.85%+44.81%+63.61%+52.65%TRVITrevi Therapeutics+0.11%+7.31%+31.90%+61.05%+240.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNUVLNuvalent$123.500.0%$108.76$71.13▼$123.69$9.76B1.155.19 million shs1.65 million shsPRAXPraxis Precision Medicines$334.79-4.5%$314.47$37.19▼$366.52$9.77B2.71701,758 shs740,097 shsTGTXTG Therapeutics$54.94-1.4%$43.01$25.28▼$57.38$8.53B1.683.02 million shs2.57 million shsTRVITrevi Therapeutics$18.65+0.1%$14.88$5.47▼$19.26$2.65B1.042.09 million shs3.10 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNUVLNuvalent-0.01%+0.05%+11.88%+16.91%+61.86%PRAXPraxis Precision Medicines-4.50%+9.63%-4.34%+4.86%+696.17%TGTXTG Therapeutics-1.40%+1.85%+44.81%+63.61%+52.65%TRVITrevi Therapeutics+0.11%+7.31%+31.90%+61.05%+240.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNUVLNuvalent 2.15Hold$127.733.42% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$569.6370.15% UpsideTGTXTG Therapeutics 2.75Moderate Buy$58.606.66% UpsideTRVITrevi Therapeutics 3.00Buy$22.6721.54% UpsideCurrent Analyst Ratings BreakdownLatest TRVI, NUVL, PRAX, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026PRAXPraxis Precision Medicines Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$537.00 ➝ $575.006/24/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$172.00 ➝ $124.006/22/2026TGTXTG Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$83.006/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$449.006/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy6/10/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/10/2026NUVLNuvalent GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$151.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/9/2026NUVLNuvalent Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$140.00 ➝ $124.006/9/2026NUVLNuvalent TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$124.00(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/APRAXPraxis Precision Medicines$8.55M1,091.69N/AN/A$34.85 per share9.61TGTXTG Therapeutics$616.29M13.65$2.76 per share19.89$4.08 per share13.47TRVITrevi TherapeuticsN/AN/AN/AN/A$1.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8619.2119.98N/A65.95%88.73%43.44%8/3/2026 (Estimated)TRVITrevi Therapeutics-$42.76M-$0.32N/AN/AN/AN/A-24.53%-23.37%8/6/2026 (Estimated)Latest TRVI, NUVL, PRAX, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million5/5/2026Q1 2026TRVITrevi Therapeutics-$0.07-$0.09-$0.02-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNUVLNuvalentN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNUVLNuvalentN/A16.1416.14PRAXPraxis Precision MedicinesN/A15.8815.88TGTXTG Therapeutics1.285.815.12TRVITrevi TherapeuticsN/A24.7524.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNUVLNuvalent97.26%PRAXPraxis Precision Medicines67.84%TGTXTG Therapeutics58.58%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipNUVLNuvalent5.02%PRAXPraxis Precision Medicines3.00%TGTXTG Therapeutics8.87%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNUVLNuvalent4079.00 million75.03 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.04 millionOptionableTGTXTG Therapeutics290153.08 million139.51 millionOptionableTRVITrevi Therapeutics20141.98 million116.00 millionOptionableTRVI, NUVL, PRAX, and TGTX HeadlinesRecent News About These CompaniesTrevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High - What's Next?June 25, 2026 | americanbankingnews.comTrevi Therapeutics Inc TRVIJune 23, 2026 | morningstar.comMTrevi Therapeutics (NASDAQ:TRVI) Upgraded to Hold at Wall Street ZenJune 20, 2026 | americanbankingnews.comTrevi Therapeutics Announces Upcoming June and July Event ScheduleJune 17, 2026 | globenewswire.comTrevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.June 4, 2026 | aol.comATrevi Therapeutics Shareholders Approve Stock and Governance ChangesJune 4, 2026 | tipranks.comTrevi Therapeutics, Inc. (TRVI) Analyst/Investor Day - SlideshowMay 15, 2026 | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 12, 2026 | seekingalpha.comTrevi Therapeutics (TRVI) Gets a Buy from H.C. WainwrightMay 8, 2026 | theglobeandmail.comTrevi Therapeutics, Inc. (TRVI) Analyst/Investor Day TranscriptMay 7, 2026 | seekingalpha.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comWhy Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030May 6, 2026 | finance.yahoo.comTrevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comTrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 5, 2026 | globenewswire.comTrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International ConferenceApril 30, 2026 | globenewswire.comTrevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026April 28, 2026 | globenewswire.comDid Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?April 24, 2026 | finance.yahoo.comTrevi Therapeutics to Participate in Upcoming May EventsApril 23, 2026 | globenewswire.comTrevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesApril 20, 2026 | globenewswire.comWhat's going on with Trevi Therapeutics stock?April 17, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026TRVI, NUVL, PRAX, and TGTX Company DescriptionsNuvalent NASDAQ:NUVL$123.50 -0.01 (-0.01%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$123.63 +0.13 (+0.10%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Praxis Precision Medicines NASDAQ:PRAX$334.79 -15.77 (-4.50%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$319.50 -15.29 (-4.57%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.TG Therapeutics NASDAQ:TGTX$54.94 -0.78 (-1.40%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$55.17 +0.23 (+0.43%) As of 06/30/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Trevi Therapeutics NASDAQ:TRVI$18.65 +0.02 (+0.11%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$18.76 +0.11 (+0.59%) As of 06/30/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
